Reported 8 months ago
EvolutionaryScale, an AI startup focusing on biology, has raised $142 million in seed funding led by Nat Friedman, Daniel Gross, and Lux Capital. The company aims to use AI to accelerate drug discovery, engineer microbes to break down plastic, and create novel proteins. This funding will support training the next generation of AI models and building partnerships with the biotech industry. EvolutionaryScale's ESM3 models will be available for research and commercially through partnerships with AWS and NVIDIA, allowing for the creation of innovative biological systems.
Source: YAHOO